Lars R. Perk
YOU?
Author Swipe
View article: Highlight selection of radiochemistry and radiopharmacy developments by editorial board
Highlight selection of radiochemistry and radiopharmacy developments by editorial board Open
Background The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biannual highlight commentary to update the readership on trends in the field of radiopharmaceutical development. Main Body This selection of highlights provid…
View article: Highlight selection of radiochemistry and radiopharmacy developments by editorial board
Highlight selection of radiochemistry and radiopharmacy developments by editorial board Open
Background The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in the field of radiopharmaceutical development. Results This commentary of highlights has res…
View article: An Explorative Study of the Incidental High Renal Excretion of [18F]PSMA-1007 for Prostate Cancer PET/CT Imaging
An Explorative Study of the Incidental High Renal Excretion of [18F]PSMA-1007 for Prostate Cancer PET/CT Imaging Open
Positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) allows for accurate diagnosis and staging of prostate cancer (PCa). Compared to other PSMA PET tracers available, [18F]PSMA-1007 is predominantly excreted via …
View article: Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers
Huntington’s Disease: A Review of the Known PET Imaging Biomarkers and Targeting Radiotracers Open
Huntington’s disease (HD) is a fatal neurodegenerative disease caused by a CAG expansion mutation in the huntingtin gene. As a result, intranuclear inclusions of mutant huntingtin protein are formed, which damage striatal medium spiny neur…